Stock AUTL AUTOLUS THERAPEUTICS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Financials Autolus Therapeutics plc

Equities

AUTL

US05280R1005

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:30:01 03/05/2024 BST 		5-day change 1st Jan Change
4.19 USD +1.95% Intraday chart for Autolus Therapeutics plc +4.75% -34.94%
05-03 European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Set to Close Week Lower MT
04-25 European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 593.8 467.6 378.4 328.8 1,120 1,114 - -
Enterprise Value (EV) 1 383.1 314.3 68.11 -53.95 879.8 436.6 529.1 449.6
P/E ratio -4.58 x -3.24 x -2.63 x -1.21 x -5.37 x -5.3 x -8 x -19 x
Yield - - - - - - - -
Capitalization / Revenue 204 x 273 x 162 x 51.7 x 660 x 36.6 x 15.6 x 5.96 x
EV / Revenue 132 x 183 x 29.2 x -8.48 x 518 x 14.3 x 7.4 x 2.41 x
EV / EBITDA -2.79 x -1.95 x -0.44 x 0.35 x - -3.49 x -3.2 x -3.1 x
EV / FCF -3.2 x -2.37 x -0.54 x 0.44 x -5.62 x -4.26 x -7.22 x 323 x
FCF Yield -31.3% -42.1% -186% 228% -17.8% -23.5% -13.9% 0.31%
Price to Book 2.33 x 2.23 x 1.51 x 1.1 x 10 x 1.89 x 2.94 x 4.34 x
Nbr of stocks (in thousands) 44,982 52,299 72,919 173,059 173,937 265,926 - -
Reference price 2 13.20 8.940 5.190 1.900 6.440 4.190 4.190 4.190
Announcement Date 03/03/20 04/03/21 10/03/22 07/03/23 14/03/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 2.908 1.715 2.33 6.36 1.698 30.47 71.52 186.9
EBITDA 1 -137.4 -160.8 -154.2 -154.3 - -125.1 -165.3 -145
EBIT 1 -142 -166.4 -162.7 -161.7 -179.7 -166.2 -146.6 -61.76
Operating Margin -4,881.77% -9,704.37% -6,981.55% -2,542.23% -10,583.1% -545.3% -205.04% -33.05%
Earnings before Tax (EBT) 1 -139 -166.3 -166 -173.2 -208.4 -187.5 -138.4 -70.66
Net income 1 -123.8 -142.1 -142.1 -148.8 -208.4 -173.6 -127 -60.44
Net margin -4,258.91% -8,285.36% -6,098.54% -2,340.24% -12,272.26% -569.68% -177.59% -32.34%
EPS 2 -2.880 -2.760 -1.970 -1.570 -1.200 -0.7906 -0.5240 -0.2202
Free Cash Flow 1 -119.8 -132.4 -126.7 -123.1 -156.6 -102.5 -73.28 1.39
FCF margin -4,120.53% -7,722.39% -5,438.54% -1,936.31% -9,221.02% -336.3% -102.46% 0.74%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 03/03/20 04/03/21 10/03/22 07/03/23 14/03/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 0.236 0.18 0.166 - 2.369 3.825 1.292 - 0.406 - 25.05 0.0536 0.1107 2.534 17.64
EBITDA - - - - - - - - - - - - - - -
EBIT 1 -40.36 -46.87 -41.62 -46.48 -43.49 -32.46 -43.1 -47.89 -47.82 -40.89 -11.68 -47.23 -49.72 -48.52 -30.79
Operating Margin -17,099.58% -26,038.89% -25,071.08% - -1,835.96% -848.71% -3,336.22% - -11,779.31% - -46.64% -88,166.74% -44,907.86% -1,914.62% -174.56%
Earnings before Tax (EBT) 1 -39.38 -48.09 -42.69 -49.53 -48.92 -32.07 -43.78 -49.02 -50.79 -64.81 -27.11 -54.05 -56.94 -55.34 -30.79
Net income 1 -33.99 -41.67 -37.06 -42.06 -42.77 -26.95 -39.81 -45.55 -45.85 -77.17 -24.69 -50.47 -53.08 -51.6 -30.79
Net margin -14,402.97% -23,147.78% -22,326.51% - -1,805.28% -704.6% -3,081.35% - -11,292.86% - -98.59% -94,211.61% -47,944.48% -2,036.21% -174.56%
EPS 2 -0.4700 -0.5100 -0.4100 -0.4600 -0.4700 -0.2300 -0.2300 -0.2600 -0.2600 -0.4500 -0.1467 -0.2200 -0.2333 -0.2333 -0.1967
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 03/11/21 10/03/22 05/05/22 04/08/22 03/11/22 07/03/23 04/05/23 03/08/23 02/11/23 14/03/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 211 153 310 383 240 678 585 665
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -120 -132 -127 -123 -157 -102 -73.3 1.39
ROE (net income / shareholders' equity) -50.8% -61.1% -54.3% -48.6% -102% -42.7% -34.3% -43.5%
ROA (Net income/ Total Assets) -44.4% -47.5% -40.6% -33.2% -48.1% -21.6% -18.5% -18.4%
Assets 1 278.9 298.9 349.9 447.9 432.8 803 685.1 328.7
Book Value Per Share 2 5.660 4.010 3.450 1.730 0.6400 2.220 1.430 0.9700
Cash Flow per Share 2 - - - - -1.060 -0.1700 -0.1800 -0.2300
Capex 1 18.3 14.7 8.86 10.8 11 13.1 12.9 14
Capex / Sales 630.71% 856.03% 380.13% 170.46% 647% 42.98% 18.1% 7.49%
Announcement Date 03/03/20 04/03/21 10/03/22 07/03/23 14/03/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Autolus Therapeutics plc

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
4.19 USD
Average target price
10.54 USD
Spread / Average Target
+151.66%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
AUTOLUS THERAPEUTICS PLC Stock Autolus Therapeutics plc
-34.94% 1.11B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+8.96% 105B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.43% 104B
ARGENX SE Stock argenx SE
+4.40% 22.94B
BIONTECH SE Stock BioNTech SE
-12.15% 22.34B
GENMAB A/S Stock Genmab A/S
-4.36% 19.25B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.08B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.04% 16.96B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.79% 14.16B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+38.61% 12.63B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. AUTL Stock
  4. Financials Autolus Therapeutics plc